POPULARITY
Categories
99 episodes with Tandem
208 episodes with Tandem
69 episodes with Tandem
30 episodes with Tandem
21 episodes with Tandem
38 episodes with Tandem
19 episodes with Tandem
27 episodes with Tandem
18 episodes with Tandem
46 episodes with Tandem
23 episodes with Tandem
15 episodes with Tandem
7 episodes with Tandem
15 episodes with Tandem
18 episodes with Tandem
7 episodes with Tandem
4 episodes with Tandem
8 episodes with Tandem
4 episodes with Tandem
8 episodes with Tandem
5 episodes with Tandem
11 episodes with Tandem
10 episodes with Tandem
9 episodes with Tandem
4 episodes with Tandem
7 episodes with Tandem
5 episodes with Tandem
5 episodes with Tandem
3 episodes with Tandem
5 episodes with Tandem
4 episodes with Tandem
6 episodes with Tandem
5 episodes with Tandem
6 episodes with Tandem
4 episodes with Tandem
7 episodes with Tandem
3 episodes with Tandem
4 episodes with Tandem
4 episodes with Tandem
3 episodes with Tandem
3 episodes with Tandem
7 episodes with Tandem
3 episodes with Tandem
2 episodes with Tandem
3 episodes with Tandem
2 episodes with Tandem
2 episodes with Tandem
4 episodes with Tandem
3 episodes with Tandem
3 episodes with Tandem
3 episodes with Tandem
2 episodes with Tandem
8 episodes with Tandem
3 episodes with Tandem
Irish Paralympian Josephine Healion joins Kathleen McNamee in studio for this week's Settle In to discuss her journey from overcoming a visual impairment diagnosis to representing Ireland in cycling events at the 2024 Paris Paralympic Games. Settle In on Off The Ball with Guinness 0.0.
Please note this episode of Type 1 on 1 contains honest discussion of severe depression at around 1'08", including suicidal thoughts. No matter how long you've been living with or close to type 1 diabetes, it remains an incredibly complex condition to understand. And while there's a wealth of information out there to dig into, knowing what to pay attention to can be just as daunting. John Pemberton is a diabetes technology consultant, children's dietician, researcher and has been living with type 1 diabetes himself for around 20 years. So if you're looking for research-backed information about the right insulin pump, want to know why 20 minutes of walking is the magic key to a stubborn high glucose reading, or you just need to start with the basics without getting overwhelmed, his diabetes education platform The Glucose Never Lies could be the answer. It was created after his young son Jude tested positive for diabetes antibodies, and when it comes to distilling complicated diabetes information and making it make sense, John is a master of the craft.In this episode we cover an incredible amount - from the professional, including his work with newly diagnosed families, the latest in diabetes research and his love of continuous glucose monitoring, to the deeply personal, including how years of undiagnosed ADHD led to severe depression and suicidal thoughts. After getting the right treatment in July 2025, John has found renewed purpose in taking The Glucose Never Lies to the next level.CONNECT WITH JOHNThe Glucose Never Lies Website The Glucose Never Lies Podcast on Spotify Diabetes Specialist Nurse Forum CGM comparison chart.DISCLAIMER Nothing you hear on Type 1 on 1 should be taken as medical advice. Please consult your healthcare team before making any changes to your diabetes or health management.JOIN THE TYPE 1 ON 1 COMMUNITY:Come and say hi @studiotype1on1 on Instagram.Visit the Type 1 on 1 website.Subscribe to the Type 1 on 1 newsletter.SPONSOR MESSAGEThis episode of Type 1 on 1 is sponsored by Dexcom. Using Dexcom CGM has given me so much confidence to make informed diabetes treatment decisions in the moment.You can choose to wear it on your arm or your abdomen, and all Dexcom CGMs have the share and follow feature even when connected to an insulin pump, so family and friends can see your glucose levels and get alerts, giving that extra bit of support when needed.Head to Dexcom.com to request a free Dexcom ONE+ sample.Always read the user manual for important product aspects and limitations. Talk to your doctor for diabetes management terms and conditions and terms of use.
Judd, Jessi, and AJ talk about some of the major line changes ahead of the Wild's game against Carolina which will see Danila Yurov act as center on the 1st line. What to expect from this shakeup and if it'll stick. Praise for Filip Gustavsson and Jesper Wallstedt, if this 'November' version of the Wild the new normal, plus more!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Judd, Jessi, and AJ talk about some of the major line changes ahead of the Wild's game against Carolina which will see Danila Yurov act as center on the 1st line. What to expect from this shakeup and if it'll stick. Praise for Filip Gustavsson and Jesper Wallstedt, if this 'November' version of the Wild the new normal, plus more!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
How do construction leaders make better decisions in a world overflowing with data? Recorded live at Autodesk University 2025, this conversation with Frank Phillips and Ashley Grassano from the University of Florida explores how curiosity, culture, and clear communication help teams turn raw information into meaningful action. Frank and Ashley share how the AEC industry can shift from reactive to proactive by embracing data literacy, asking better questions, and building trust between the field and the office. From forecasting risks to creating visibility across teams, this episode highlights how decision-making improves when people, process, and technology finally align. In this episode you'll learn: Why curiosity (not dashboards) is the real driver of innovation How data transparency builds trust across construction teams Practical steps for improving decision-making in fast-paced environments MEET OUR GUESTS Frank Phillips is Director of Business Affairs Technical Services at University of Florida, where he has over two decades of career experience. Ashely Grassano is Space & GIS Manager at the University of Florida. She manages a team of BIM Coordinators, Space Planners, and GIS Administrators. TODD TAKES Make Old Buildings Smarter, Not “Smart” A campus-wide push toward digital twins is turning legacy facilities into data-ready assets. The playbook: uplift Revit to a consistent minimum spec, link key MEP assets for location and maintenance, stream live data into Tandem, and anchor everything with GIS. It's practical, phased modernization—form meets function. Data Is an Asset—Treat It Like One Ownership and flow matter. From ACC adoption to Cost rollout, success comes from redefining processes (not lift-and-shift), onboarding project-by-project, and measuring wins by outcomes (like contractors getting paid). The ethos: the owner funds the work, the owner owns the data—and partners help operationalize it. Scan, Map, Connect—and Then Automate LiDAR for utilities and interiors, geospatially aligned campus models, ACC + Tandem integration, and emerging AI/API upgrades (including easier auth) are building a true “smart campus” foundation. Pair top-down sponsorship with bottom-up field buy-in, and you get faster finds at 2 a.m., fewer “unknowns,” and clearer ROI. MORE RESOURCES Thanks for listening! Please be sure to leave a rating and/or review and follow up our social accounts. Bridging the Gap Website Bridging the Gap LinkedIn Bridging the Gap Instagram Bridging the Gap YouTube Todd's LinkedIn Thank you to our sponsors! Graitec North America Graitec North America LinkedIn Autodesk's Website Other Relevant Links: Frank's LinkedIn Ashley's LinkedIn University of Florida
Tandem's Investment Team returns with Episode 22 of Tandem Talk! Tune in as the team explores the powerful passive investing feedback loop that pushes market leaders higher, a self-fulfilling prophecy in its own right—until it reverses. They discuss how extreme concentration can distort performance, the puzzle that is AI-expenditure, and what these trends may signal in an increasingly unpredictable environment.
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
Join Coach g on the Tandem Talk Show as he interviews Kathy Baber, a solo-living nonprofit professional who lost over 30 pounds and six pant sizes through Tandem's Metabolic Reset Program. Kathy shares how she balanced real life — frequent dining out, a busy travel schedule, and holidays — with a sustainable plan that didn't require a gym membership or extreme restriction. Topics covered include the role of accountability and coaching (Coach Lisa), practical tools Kathy used (Fitbit, food scale, walking pad, dumbbells), and how the Tandem app helped her track macros, calories, water, and particularly sodium — a key insight that reduced water retention and accelerated progress. Kathy also explains how she adapted meal plans, enjoyed favorites like protein-powered pancakes, and used the app to pre-log and balance indulgences like wine or treats around social events. The episode highlights the coaching support Kathy received (twice-weekly check-ins and restaurant-specific guidance), the non-cookie-cutter nature of the program, and the mental and emotional benefits of her transformation — from improved confidence and headshots to potential health improvements like lower cholesterol. Kathy offers advice for listeners on approaching the program with an open mind, asking questions, and using the app community for ongoing support. Expect practical tips for tracking while eating out, strategies for maintaining social life and progress through holidays, and inspiring evidence that steady, measured changes plus accountability can deliver big results without giving up the foods you love or living in a gym.
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922. WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups. Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life. Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software. Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population. We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/ XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool. Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models. Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy. https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,. Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity. The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits. The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age. The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said. The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias." Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences. Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative. Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year. "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives." Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org. "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us." Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market. About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com. About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing. Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet. Learn more at aemanncharities.org. About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
We've got an update from Tandem Diabetes. We're talking about Libre 3 plus integration, Lyumjev approval, Mobi tubeless, extended wear infusion sets and a lot more with VP of Product Management Marisa Fienup. She's also answering your questions about tubing, alerts, and shares what's next. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Information on RocketAP and other closed loop research Tandem earnings call info here Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
This week I'm speaking to the lovely Gabby from Edinburgh about her experiences with tandem breastfeeding her two children, who are three and a half years and 10 months old. Gabby discusses the practicalities and challenges of her tandem feeding journey, including co-sleeping, night weaning, and dealing with her eldest child's sleep apnea. She shares her struggles with breastfeeding her younger child, who initially refused to latch due to her infection, and the steps she took, including seeking professional help, to successfully re-establish breastfeeding. Gabby also talks about her health conditions, including Ehlers-Danlos Hypermobility Syndrome and Ankylosing Spondylitis, and how breastfeeding has proven to be protective for her own health.My picture book on how breastfeeding journeys end, The Story of Jessie's Milkies, is available from Amazon here - The Story of Jessie's Milkies. In the UK, you can also buy it from The Children's Bookshop in Muswell Hill, London. Other book shops and libraries can source a copy from Ingram Spark publishing.You can also get 10% off my books on supporting breastfeeding beyond six months and supporting the transition from breastfeeding at the Jessica Kingsley press website, that's uk.jkp.com using the code MMPE10 at checkout.Follow me on Instagram @emmapickettibclc or find out more on my website www.emmapickettbreastfeedingsupport.comResources mentioned - We talked about Carla Rodrigues https://www.latchworld.co.uk/Stretched to the Limits by Rachel Fitz-Desorgher https://www.hachette.co.uk/titles/rachel-fitz-desorgher-2/stretched-to-the-limits/9781839972492/ This podcast is presented by Emma Pickett IBCLC, and produced by Emily Crosby Media.
L'ensemble des liens utiles : Besoin de former vos managers via notre Yaniro Leadership Program ? Prenez rendez-vous iciEnvie d'envoyer à vos managers la version auto-administrée de notre formation au management ? C'est ici : https://yanirowiki.co/kitEt pour retrouver les meilleures pratiques RH directement dans notre Yaniro Wiki c'est ici : https://yanirowiki.co/Découvrez un extrait du podcast de Yaniro avec comme invité Johann Vivier qui est Chief People Officer chez Smartbox.
Emma Friedman reports.See omnystudio.com/listener for privacy information.
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
Air Mauritius Staff Association : un nouveau souffle avec avec le tandem Megh Pillay et Andre Viljoen by TOPFM MAURITIUS
Air Mauritius Staff Association : un nouveau souffle avec avec le tandem Megh Pillay et Andre Viljoen by TOPFM MAURITIUS
Tim spricht in dieser Folge mit Bernd Joussen über den Einfluss auf die Retrospektive, den Product Owner tatsächlich haben. Bernd ist erfahrener Produkt- und Projektmanager, Scrum Master und Agile Coach und war schon mehrfach Gast im Podcast. Beide erleben in ihrer Arbeit mit Teams, dass viele Product Owner den Raum der Retro missverstehen. Manche treten zu dominant auf und hemmen den Austausch. Andere ziehen sich so weit zurück, dass sie kaum Wirkung entfalten. Dabei ist die Retrospektive ein gemeinsamer Ort des Lernens. Der Product Owner gehört dorthin, weil er Teil des Teams ist und mit seinem Verhalten darüber entscheidet, wie offen gesprochen werden kann. Bernd beschreibt, dass eine Retro ohne Vertrauen keine Wirkung zeigt. Wenn Teams einmal darum bitten, eine Runde ohne Product Owner durchzuführen, sei das ein Signal, das ernst genommen werden sollte. Kein Anlass zur Verteidigung, sondern zur Selbstreflexion. Denn Vertrauen entsteht nicht durch Argumente, sondern durch Haltung. Wer als Product Owner offen zuhört, statt zu bewerten, gibt dem Team die Sicherheit, auch heikle Themen anzusprechen. In vielen Organisationen hängt der Einfluss auf die Retrospektive stark von der Persönlichkeit des Product Owners ab. Wer laut ist, prägt die Dynamik schnell. Wer zurückhaltend ist, verliert an Gewicht. Beides kann den Austausch verzerren. Ein guter Product Owner kennt die Wirkung seiner Präsenz und achtet darauf, Raum zu geben. Bernd betont, dass die Moderation des Scrum Masters hier entscheidend ist. Sie schafft Balance zwischen allen Stimmen und schützt den Raum vor einseitigen Perspektiven. Der Einfluss auf die Retrospektive zeigt sich nicht in Redebeiträgen, sondern in Haltung. Ein Product Owner, der echtes Interesse am Team zeigt, Fragen stellt und neugierig bleibt, trägt mehr zur Verbesserung bei als jemand, der Ergebnisse einfordert. Gute Retrospektiven entstehen, wenn alle gemeinsam Verantwortung übernehmen. Wenn der Product Owner das Team unterstützt, Lösungen zu finden, statt sie vorzugeben. Tim beschreibt, dass gerade in produktorientierten Teams die Retro oft zu stark auf Prozesse schaut und zu wenig auf Wirkung. Dabei bietet sie die Chance, über Outcomes zu sprechen, über den Beitrag des Teams zum Produktwert. Wenn der Product Owner diesen Blick einbringt, erweitert er die Perspektive, ohne den Rahmen zu sprengen. Dann wird die Retrospektive zu einem Ort, an dem Teamleistung und Produkterfolg zusammenfinden. Bernd sieht in reifen Teams eine Selbstverständlichkeit, mit der Product Owner und Scrum Master gemeinsam für diese Qualität sorgen. Sie verstehen sich als Tandem, das das Team befähigt, eigene Lösungen zu entwickeln. Wo diese Verbindung fehlt, bleibt die Retro oberflächlich. Gute Zusammenarbeit zwischen Scrum Master und Product Owner sorgt dafür, dass Themen wie Vertrauen, Konflikte oder Verantwortung auch mit Blick auf den Produkterfolg besprochen werden. Der Einfluss auf die Retrospektive hängt also davon ab, wie bewusst ein Product Owner seine Rolle lebt. Wer mit Neugier und Ruhe in die Retro geht, stärkt das gemeinsame Lernen. Wer sich als Teil des Teams begreift, fördert Offenheit. Und wer Verantwortung für die Wirkung seiner Worte übernimmt, schafft die Grundlage für Weiterentwicklung. Gute Retrospektiven entstehen dort, wo Menschen zuhören, lernen und handeln – gemeinsam und mit echtem Interesse aneinander. Frühere Episoden mit Bernd Joussen in diesem Podcast: - Konflikte mit Stakeholdern meistern - von Spannungen zu Lösungen - Herausforderungen zwischen Product Owner und Developer Wenn ihr direkt mit Bernd Joussen in Kontakt kommen möchtet, erreicht ihr ihn über sein LinkedIn-Profil. Weitere Informationen über Bernd Joussen und sein Angebot als Konfliktbegleiter, Experte für Retrospektiven mit Führungskräften und als Teamentwickler findet ihr auf seiner Webseite der-teamdynamo.de. Ein ganz besonderes Format rund um Retrospektiven und v.a. für Scrum Master und Team Coaches bietet Bernd alle
La entrada Mimolive Owncast el tandem perfecto se publicó primero en Blog Xavi74.
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
Pravděpodobný příští premiér Andrej Babiš (ANO) chce obnovit společná zasedání české a slovenské vlády. Ta byla v minulém roce přerušena kvůli neshodám v klíčových zahraničních tématech, především v otázce války na Ukrajině. „Je to kaňka, která bude doufám brzy napravena,“ oceňuje místopředseda hnutí ANO Radek Vodnráček Babišův záměr. „Ať vztahy obnoví, ale neuškodí tím české pozici,“ apeluje v Pro a proti Českého rozhlasu Plus europoslanec Jan Farský (STAN).
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
Pravděpodobný příští premiér Andrej Babiš (ANO) chce obnovit společná zasedání české a slovenské vlády. Ta byla v minulém roce přerušena kvůli neshodám v klíčových zahraničních tématech, především v otázce války na Ukrajině. „Je to kaňka, která bude doufám brzy napravena,“ oceňuje místopředseda hnutí ANO Radek Vodnráček Babišův záměr. „Ať vztahy obnoví, ale neuškodí tím české pozici,“ apeluje v Pro a proti Českého rozhlasu Plus europoslanec Jan Farský (STAN).Všechny díly podcastu Pro a proti můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.
Welcome to the Thousand Stories podcast, the Renaissance Series.Join host Justin Brown, former Secretary of Human Services for the state of Oklahoma, and his new co-host, Luke Williams, President of Tandem Research, as they explore a true rebirth for human services.The Renaissance Series is dedicated to illuminating the stories and ideas that define this new era of innovation and transformation. We are moving toward a connected, human-centered, and innovative future in health and human services (HHS). We explore how leaders, researchers, and practitioners are building systems that truly serve people.Justin Brown originally launched the Thousand Stories podcast to share the incredible untold stories happening in Health and Human Services beyond the challenges and negative headlines. Now, the conversation centers on the belief that we are at the dawn of a renaissance in HHS, positioned at the intersection of experienced leadership and new technology innovations that can supercharge this transformation.The mission is to rethink the current system, which often operates as a "one-size-fits-all approach" that catches people at the bottom. Instead, we advocate for a custom safety net that follows us wherever we go, employing strategic interventions. This shift is essential for promoting dignity, creating better outcomes for future generations, and achieving greater efficiency for taxpayers.To achieve this, we must focus on delivery model transformation by working to remove systemic barriers (like those related to transportation, language, child care, and stigma) that prevent customers from accessing resources. A core goal is to move upstream to a more preventative posture, meeting people before they fall into crisis, preventing engagement with intrusive systems like child welfare.This series draws heavily on the research conducted by Luke Williams and Tandem Research, including their national catalog of delivery model innovations that covers 46 cases across over 38 states.In this episode, the hosts focus on the physical delivery of health and human services and the eight categories of innovation currently reshaping the field:Community Partnerships: Services delivered through formal agreements with local nonprofits, sometimes utilizing embedded workers or licensed nonprofit workers.Collocation: Partnerships between public entities, such as the one-stop shop model.Real Estate Modernization: Strategically streamlining physical office space, often coupled with distributing the workforce into the community.Mobile Service Delivery: Utilizing gutted buses or vans to provide intake and eligibility determinations in rural areas, disaster areas, or to alleviate the burden on overwhelmed physical offices.Intensive Case Management: Giving workers the tools to develop long-term career or educational pathways.Integrated Online Portals: Utilizing tools like robotic process automation (RPA) and AI for proactive intake and eligibility identification across services and agencies.Modernized Contact Centers: Using AI as a "switchboard operator" or "front man" to direct callers to specialized human teams.Tech-Driven Case Management: Using emerging technologies like AI to analyze customer data for predictive capabilities (e.g., anticipating a life event that changes service eligibility) or detecting fraud.While technology is a critical component for systems to move upstream, the hosts emphasize that the physical in-person experience is critical and will remain important for the foreseeable future, making intentional planning for the physical footprint essential. Discover how leaders are creating a meaningful and intentional mix of purpose-built physical spaces and distributed models to serve people at their most vulnerable times.
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
In Part 2, Ian Wookey takes us inside daily flying with 450 Tactical Helicopter Squadron, sharing what it's like to operate the CH-147F Chinook in challenging environments. He talks about crew coordination, tactical missions, mountain flying, and the training and experience required to upgrade from First Officer to Aircraft Commander in Canada's heavy-lift helicopter community.
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
We get into the world of Tandem adventures with Di and Colin, a dynamic duo from Scotland who first rode a tandem bike on a blind date and haven't looked back since. They share about their adventures through the UK and France, and how a recent stage 4 Prostate Diagnosis has focused them more sharply on continuing to live life to the full. Follow them on the socials - FacebookRead their blog - Matilda's MusingsDonate to their fundraiserCheck out Zorali for all your outdoor adventure needs! Check out Ombraz Sunglasses - I'm a fan and I think you will be too!Support the showBuy me a coffee! I'm an affiliate for a few brands I genuinely use and recommend including:
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
Wir sprechen über aktuelle Lichttechnik am Fahrrad und das High Velocity Research, ein Rennen für Räder aus Resten. (00:00:00) Begrüßung (00:02:21) Klingeln bei Klötzer: Fahrradlicht (00:03:39) Der wichtigste Tipp: Licht richtig einstellen (00:09:30) Stand der Technik bei Dynamo-Scheinwerfern (00:12:18) Rücklichter für Dynamo (00:13:13) Akku-Frontlichter (00:15:33) Akku-Rücklicht (00:22:00) Verschiedenes zur Zukunft am Lichtmarkt (00:32:34) Nachtrag zu Menschen zu Fuß und im Rollstuhl (00:33:36) Ausfahrt des Monats: High Velocity Research (00:35:29) Glücksrad und Wundertüten (00:40:02) Pauls 29er Hardtail (00:41:26) Tonis 20-Zoll-Rad (00:44:04) Inspiration durch das Hack Bike Derby (00:47:24) Das Mini Bike Fest (00:51:39) Nachbesprechung und Einladung ins Peloton (00:52:50) Musik: Wet Leg – mangetout Hier findet ihr einen Bericht zum High Velocity Research: https://bikepacking.com/plog/high-velocity-research-trash-metal-framebuilding-competition-2025/ Hier findet ihr mehr zum Mini Bike Fest der 20inch_ultras: https://www.instagram.com/mini_bike_fest/ Hier könnt ihr uns bei Steady unterstützen: https://steadyhq.com/de/antritt/about Hier entlang geht's zu den Links unserer Werbepartner: https://detektor.fm/werbepartner/antritt >> Artikel zum Nachlesen: https://detektor.fm/gesellschaft/antritt-licht-am-fahrrad-und-high-velocity-research
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
Due voci, una sola direzione: il divertimento!Michael Casanova e Danny Morandi tornano insieme su Radio 3i per accompagnarti in un viaggio fatto di risate, musica e tanta energia. Dal lunedì al giovedì dalle 16 alle 18 e il venerdì dalle 15 alle 18, sali anche tu sul nostro tandem radiofonico: una pedalata a due che diventa un giro infinito di emozioni grazie agli ascoltatori, veri compagni di avventura!
In the conclusion of this two-part story, we talk with "Brian" who will share about his work with Dana Brown, Executive Director of Tandem's Mentorship about the challenging but important work of restorative justice. Brian's story highlights how cultural norms can influence the perpetration of sexual crimes but finally how accountability, empathy, and community support can bring validation and restoration to survivors while helping prevent future harm. We hope this story sparks conversations that support survivors, challenge harmful norms, and encourage prevention. Learn more at fiercefreedom.org
Ever wondered what it would be like to travel through a country on a Tandem bicycle? This week Federico and Baaska are going to tell us all about their experience and a day cycling in MalaysiaFollow them on instagram - @Fedenbaaska I'm also shouting out fans who responded to my Instagram Question - What is your luxury item for bike travel.Check out Zorali for all your outdoor adventure needs!Support the showBuy me a coffee! I'm an affiliate for a few brands I genuinely use and recommend including:
BT and Sal dive into the Aaron Glenn debate, energized by a caller who suggests the Jets coach isn't "scared to lose, but scared to win." The hosts dissect Glenn's seemingly hesitant decision-making, comparing him to Brian Daboll's fearless, early-career gambles. While acknowledging that Justin Fields' poor play is a factor, they argue Glenn is not absolved from making "horrific decisions." The conversation quickly escalates into a "Harbaugh Watch," with Sal questioning whether the Jets should pull the plug on Glenn after one season if a known commodity like John Harbaugh unexpectedly becomes available. Plus, a quick look at the Jets' possible trade targets (Olave, Waddle) and a preview of the upcoming Yankees press conference with Boone and Cashman.
The Alan Cox Show
The Alan Cox ShowSee omnystudio.com/listener for privacy information.
In this two-part episode, we talk with "Brian" who will share about his work with Dana Brown, Executive Director of Tandem's Mentorship about the challenging but important work of restorative justice. Brian's story highlights how cultural norms can influence the perpetration of sexual crimes but finally how accountability, empathy, and community support can bring validation and restoration to survivors while helping prevent future harm. We hope this story sparks conversations that support survivors, challenge harmful norms, and encourage prevention. Learn more at fiercefreedom.org
In this episode of Your Diabetes Insider Podcast, Ben breaks down everything you need to know about insulin pumps - what's out there, how they work, and whether switching from injections is worth it. He covers the pros and cons of top options like Omnipod, Tandem, and Medtronic, shares real talk on convenience vs. reliability, and gives tips for figuring out which system fits your lifestyle best. If you've ever wondered, “Should I get a pump—or stick with shots?” this episode will help you decide. Want the best blood sugars you've ever had while enjoying great food? Peep this: https://www.yourdiabetesinsider.com/coaching RESOURCES: Download these FREE guides that will help you on your diabetes, nutrition, and exercise journey! https://www.yourdiabetesinsider.com/free-stuff Watch my food breakdowns here → https://www.youtube.com/@yourdiabetesinsider LET'S TALK! Instagram: @manoftzeel Tiktok: @manoftzeel
Leslie shares her teen's type 1 diabetes diagnosis and DKA, rapid self-management with Dexcom G7 and Tandem t:slim Control-IQ, ADHD challenges, camp chaos, and parenting tactics that build independence. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Tandem Mobi ** twiist AID System Drink AG1.com/Juicebox Use code JUICEBOX to save 40% at Cozy Earth CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof. ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan. If the podcast has helped you to live better with type 1 please tell someone else how to find it!
With over 10,000 AI tools at our fingertips, it's tempting to think technology will be our golden ticket to efficiency, profits, and free time. The problem? All that "help" can actually lead to tech creep—where one more tool, one more subscription, and one more DIY task sneak onto your plate until your calendar is full and your marriage is on the back burner. Bottom line: Tech can absolutely help you grow your business and free up more time for your marriage—if you use it in moderation and keep your focus on the high-level work only you can do.
In this episode, Lex speaks Mike Sha - the CEO and co-founder of Tandems (formerly SigFig), a leading provider of AI-powered software for wealth management firms and financial institutions. Together, Lex and Mike discuss the evolution of wealth technology through the lens of Mike's entrepreneurial journey from founding Wikinvest in 2006 to building Tandems. Wikinvest pivoted to portfolio tracking and then to a B2B model, powering major portals like Yahoo Finance and managing over $500 billion in tracked assets. The team's insights into poor retail investment behavior led to building SigFig, a B2B robo-advisor, eventually serving banks like UBS and Wells Fargo.Today, rebranded as Tandems, the firm offers AI-powered tools for advisors across three key areas: meetings, asset gathering, and investment management, with AI integrated via a modular “wealth OS” platform. Tandems uses an open architecture for AI, prioritizing trust, configurability, and high accuracy tailored to the specific workflows of financial advisors. NOTABLE DISCUSSION POINTS:The Realization That Most Investors Struggle on Their Own Sparked the Robo-Advisory Movement - Mike Sha's early data from tracking $400–500 billion in retail portfolios across Yahoo!, CNN, and other finance portals revealed that most individuals consistently underperform when managing their own investments. This insight directly led to the creation of SigFig, one of the first robo-advisors, designed to make high-quality investment advice affordable and automated. It shows how data-driven observation of user behavior can uncover market inefficiencies and spark new product categories.Distribution and Integration Trumps Pure Innovation in Fintech Partnerships - Tandem's evolution from a consumer-facing platform to a B2B software provider for major banks underscored a critical lesson: distribution and trust are the hardest parts of scaling in financial services. Rather than trying to replace institutions, Sha's team embedded within them - learning that success requires deep integration with legacy systems and respect for the bank's compliance and operational frameworks. The “secret” to working with large financial institutions, Sha notes, is understanding their old infrastructure and designing around it - not fighting it.AI's Real Impact in Wealth Management Will Begin with Eliminating Repetitive Work - Tandem's current strategy focuses on AI automation for financial advisors, not as a replacement but as an assistant. Sha highlights that over 90% of an advisor's day involves repetitive administrative work - meeting prep, paperwork, compliance, follow-ups. Tandem's “Wealth OS” connects legacy systems and uses AI to automate these tasks first, freeing advisors to focus on human relationship-building and advice. It's a practical and near-term vision of AI in finance: efficiency before intelligence. TOPICSTandems, SigFig, Wikinvest, wealthtech, wealth management, fintech, ai, artificial intelligence, investment, roboadvisors, finance, financial management, banking, bank partnerships ABOUT THE FINTECH BLUEPRINT
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sanofi lowers prices, oral pill for T1D prevention studied, updates from Medtronic, Tandem, and Sequel Med Tech, falsely lower A1Cs (and why that happens), Biolinq gets FDA okay for micro-needle CGM and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX French drugmaker Sanofi says it would offer a month's supply of any of its insulin products for $35 to all patients in the U.S. with a valid prescription, regardless of insurance status. The program, originally meant for uninsured diabetes patients, would now include those with commercial insurance or Medicare, the drugmaker said. Patients will be able to purchase any combination, type, and quantity of Sanofi insulins with a valid prescription for the fixed monthly price of $35, starting January 1. Lilly and Novo also have similar programs through which they offer insulin products for $35 a month for U.S. patients regardless of whether the patients have insurance. There is no law at work here – the only legislation that has changed the price of insulin came with the Inflation Reduction Act in 2022 with the Medicare cap. Helping lower the cost here, biosimilars hitting the market and the huge profitability for GLP-1 drugs for Novo and Lilly https://www.reuters.com/business/healthcare-pharmaceuticals/sanofi-offer-all-insulin-products-35-per-month-us-2025-09-26/ XX A pill typically prescribed for rheumatoid arthritis and alopecia might help slow the progression of type 1 diabetes, a new study says. Baricitinib (bare-uh-SIT-nib) safely preserved the body's own insulin production in people newly diagnosed with type 1 diabetes.. and their diabetes started progressing once they stopped taking baricitinib, results show. They produced less insulin and had less stable blood sugar levels. Baricitinib works by quelling signals in the body that spur on the immune system, and is already approved for treating autoimmune conditions such as rheumatoid arthritis, ulcerative colitis and alopecia, researchers said. “Among the promising agents shown to preserve beta cell function in type 1 diabetes, baricitinib stands out because it can be taken orally, is well tolerated, including by young children, and is clearly efficacious,” Waibel said. “We are hopeful that larger phase III trials with baricitinib are going to commence soon, in people with recently diagnosed type 1 diabetes as well as in earlier stages to delay insulin dependence,” she added. “If these trials are successful, the drug could be approved for type 1 diabetes treatment within five years.” Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. https://www.usnews.com/news/health-news/articles/2025-09-23/pill-effective-in-slowing-type-1-diabetes-progression XX An existing transplant drug has shown promise in slowing the progression of type 1 diabetes in newly diagnosed young people, potentially paving the way for the first therapy that modifies the disease after diagnosis. The Drug, called ATG, is currently used together with other medicines to prevent and treat the body from rejecting a kidney transplant. It can also be used to treat rejection following transplantation of other organs, such as hearts, gastrointestinal organs, or lungs. The researchers studied 117 people aged five to 25, who'd been diagnosed with type 1 diabetes within the past three to nine weeks. The participants were from 14 centers across eight European countries and were randomized to be given different doses of ATG (0.1, 0.5, 1.5, or 2.5 mg/kg) or a placebo. ATG was given as a two-day intravenous (IV) infusion. The main goal was to see how well the pancreas could still make insulin after 12 months, measured by C-peptide levels during a special meal test. C-peptide is released into the blood along with insulin by the pancreas. The findings are promising, showing that ATG, even at a relatively low dose, can slow the loss of insulin-producing cells in young people newly diagnosed with type 1 diabetes. The lower dose also caused fewer side effects, making it a more practical option. https://newatlas.com/disease/antithymocyte-globulin-newly-diagnosed-type-1-diabetes/ XX The FDA has delayed its feedback on Lexicon Pharmaceuticals' application to bring Zynquista (sotagliflozin) to people with type 1 diabetes. The agency had planned to respond this month but will now wait until the fourth quarter after reviewing new data from ongoing studies. Zynquista, an oral drug meant to be used with insulin, has already been approved for heart failure (marketed as Inpefa). But in type 1 diabetes, it faces safety concerns: last year an FDA advisory committee voted 11–3 that its benefits don't outweigh the increased risk of diabetic ketoacidosis (DKA). The FDA later issued a complete response letter rejecting the drug. Lexicon is still pushing forward, hoping its additional submissions will strengthen Zynquista's case for type 1 diabetes approval. https://www.biospace.com/fda/after-fda-rejection-lexicons-type-1-diabetes-drug-hit-with-another-regulatory-delay XX A common but often undiagnosed genetic condition may be causing delays in type 2 diabetes diagnoses and increasing the risk of serious complications for thousands of Black and South Asian men in the UK—and potentially millions worldwide. A new study found around one in seven Black and one in 63 South Asian men in the UK carry a genetic variant known as G6PD deficiency. Men with G6PD deficiency are, on average, diagnosed with type 2 diabetes four years later than those without the gene variant. But despite this, fewer than one in 50 have been diagnosed with the condition. G6PD deficiency does not cause diabetes, but it makes the widely used HbA1c blood test—which diagnoses and monitors diabetes—appear artificially low. This can mislead doctors and patients, resulting in delayed diabetes diagnosis and treatment. The study found men with G6PD deficiency are at a 37% higher risk of developing diabetes-related microvascular complications, such as eye, kidney, and nerve damage, compared to other men with diabetes. "This study highlights important evidence that must be used to tackle these health inequalities and improve outcomes for Black communities. Preventative measures are now needed to ensure that Black people, especially men, are not underdiagnosed or diagnosed too late." https://medicalxpress.com/news/2025-09-hidden-genetic-delay-diabetes-diagnosis.html XX Novo Nordisk today announced the resubmission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Awiqli® (insulin icodec) injection, a once-weekly basal insulin treatment for adults living with type 2 diabetes. If approved, Awiqli® would become the first once-weekly basal insulin available in the United States, providing an alternative to daily basal insulin injections for adults living with type 2 diabetes. The resubmission is based on results from the ONWARDS type 2 diabetes phase 3a program for once-weekly Awiqli® which is comprised of five randomized, active-controlled, treat-to-target clinical trials in approximately 4,000 adults with type 2 diabetes. The clinical program evaluated Awiqli® vs. daily basal insulin and the primary endpoint in these trials was change in A1C from baseline.1-5 Awiqli® is approved in the EU, along with 12 additional countries. In addition, regulatory filings have been completed in several other countries, with further regulatory decisions expected in 2025. XX Interesting news from Sequel Med Tech – they've signed an agreement with Arecor to pair the twiist pump with AT278 an ultra-concentrated (500U/mL), ultra-rapid insulin in development. They also have a deal with Medtronic to develop insulin for new pumps. This insulin isn't yet approved, it's 5 times stronger than standard fast acting it's hoped that a clinical study will begin next year. Arecor says its insulin could potentially be the only option capable of enabling and catalyzing the next generation of longer-wear and miniaturized automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-arecor-develop-rapid-insulin-twiist/ XX Tandem Diabetes Care announes its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use with Eli Lilly and Company's Lyumjev® (insulin lispro-aabc injection) ultra-rapid acting insulin in the United States (U.S.). – The t:slim X2 insulin pump with Control-IQ+ technology is now cleared for use with Lyumjev for people with type 1 diabetes ages 2 and above and all adults with type 2 diabetes. The companies are continuing to work toward securing Lyumjev compatibility for the Tandem Mobi pump. https://hitconsultant.net/2025/09/29/tandem-diabetes-cares-tslim-x2-pump-cleared-for-use-with-lillys-ultra-rapid-lyumjev-insulin/ XX You can now place your order for the MiniMed™ 780G system with the Instinct sensor, made by Abbott. And if you are already a MiniMed 780G user, you can place an upgrade order today. This is a 15 day wear sensor, with no transmitter or overtape required. It looks the same at other Abbot sensors such as the Libre but is proprietary to Medtronic. Shipments are scheduled to start in November. https://www.drugdeliverybusiness.com/medtronic-launches-minimed-780g-instinct-abbott/ XX The global type 1 diabetes (T1D) burden continues to increase rapidly driven by rising cases, ageing populations, improved diagnosis and falling death rates. , The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040. However, due to lack of diagnosis and challenges in collecting sufficient data, the actual number of individuals living with T1D is likely much higher, researchers say. In fact, they estimate that there are an additional 4.1 million 'missing people' who would have been alive in 2025 if they hadn't died prematurely from poor T1D care, including an estimated 669,000 who were not diagnosed. This is particularly true in India, where an estimated 159,000 people thought to have died from missed diagnoses. The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old. Finland is projected to have the highest incidence of T1D in children aged 0-14 years in 2025 at around 64 cases per 100,000. The substantial increases in T1D forecasts between 2025 and 2040 underscore the urgent need for action. As co-author Renza Scibilia from Breakthrough T1D explains, "Early diagnosis, access to insulin and diabetes supplies, and proper healthcare can bring enormous benefits, with the potential to save millions of lives in the coming decades by ensuring universal access to insulin and improving the rate of diagnosis in all countries." The authors note some important limitations to their estimates, including that while the analysis uses the best available data, predictions are constrained by the lack of accurate data in most countries-highlighting the urgent need for increased surveillance and research. They also note that data on misdiagnosis and adult populations remain limited, and the analysis assumes constant age-specific incidence and mortality over time. Furthermore, incidence data from the COVID-19 period were excluded from part of the modelling to avoid bias. Future updates are expected to improve as new data become available and applied. https://www.news-medical.net/news/20250919/New-study-warns-of-millions-of-undiagnosed-and-missing-people-with-type-1-diabetes.aspx XX A new study has found that semaglutide — the active ingredient found in some GLP-1 medications prescribed for diabetes and to aid weight loss — may help protect the eyes from diabetic retinopathy. Researchers estimate that as much as 40% of all people with diabetes also have diabetic retinopathy — a potentially blinding eye condition caused by blood vessel damage in the eye's retina. There is currently no cure for diabetic retinopathy. The condition is often managed through injections of anti-VEGF medications into the eye, surgery, and blood sugar monitoring and control. For this lab-based study, researchers used samples of human retinal endothelial cells that were treated with different concentrations of semaglutide. The cells were then placed in a solution with both a high glucose level and high level of oxidative stress — where there is an imbalance of antioxidants and free radicals — for 24 hours. Past studies show that oxidative stress plays a role in the formation of diabetic retinopathy. At the study's conclusion, researchers found that the retinal cells treated with semaglutide were twice as likely to survive than cells that were untreated. Additionally, the treated cells were found to have larger stores of energy. Scientists also found that three markers of diabetic retinopathy were decreased in the semaglutide-treated retinal cells. First, the levels of apoptosis — a form of cell death — decreased from about 50% in untreated cells to about 10% in semaglutide-treated cells. The production of the free radical mitochondrial superoxide decreased from about 90% to about 10% in the treated retinal cells. Researchers also found the amount of advanced glycation end-products — harmful compounds that can collect in people with diabetes and are known to cause oxidative stress — also decreased substantially. Lastly, scientists reported that the genes involved in the production of antioxidants were more active in the semaglutide-treated cells when compared to untreated cells. Researchers believe this is a sign that semaglutide may help repair damage to the retinal cells. “Our study did not find that these drugs harmed the retinal cells in any way — instead, it suggests that GLP1-receptor agonists protect against diabetic retinopathy, particularly in the early stages,” Ioanna Anastasiou, PhD, molecular biologist and postdoctoral researcher at the National and Kapodistrian University in Greece, and lead author of this study, said in a press release. “Excitingly, these drugs may be able to repair damage that has already been done and so improve sight. Clinical trials are now needed to confirm these protective effects in patients and explore whether GLP-1 receptor agonists can slow, or even halt, the progression of this vision-robbing condition.” https://www.medicalnewstoday.com/articles/ozempic-semaglutide-may-help-protect-against-diabetes-related-blindness-retinopathy XX Biolinq has received De Novo Classification from the U.S. Food and Drug Administration for its lead product, Biolinq Shine, a patch on the forearm that provides real-time glucose feedback through a primary color-coded LED display, visible with or without a phone. This one is tricky – it's called a needle free CGM but it also says it uses micro needles. By the way, De Novo isn't exactly the same as what we think of for FDA approval for medical devices. It's not as rigorous but it's a streamlined route for novel, low to moderate risk devices with no existing equivalent. We'll see how this one turns out. https://www.hmenews.com/article/biolinq-s-multi-function-biosensor-receives-fda-de-novo-classification
This week on Happy Mum Happy Baby we say hiya to actress, presenter and mother of four Joanna Page!Joanna opens up to Gi about life after Gavin & Stacey, and shares how she juggles the chaos of raising four children (and many pets!) alongside her acting career.She also reflects on the complications she faced during pregnancy, as well as her experience of becoming pregnant again at 44.Joanna's new autobiography Lush!: My Story - From Swansea to Stacey and Everything in Between is available now! Hosted on Acast. See acast.com/privacy for more information.
The Race is back ! For the kickoff of The Amazing Race Season 38, Brice is switching things up on the Pitstop. While Brooke is living her best life in Europe, our good friend Sasha Joseph (@funsize_04) steps in to break down all the twists and turns of Episode 1. From icy strikes on the rink, cheese wheels in Edam, to flower power in the greenhouse, Brice and Sasha are just vibin' as they unpack the premiere. We're talking Express Pass drama, Hazard struggles, and first impressions of this Big Brother–meets–Race cast. You already know the vibes are high and the energy is flowing—don't miss it!
Purple Pants Podcast | Twins, Twists & Tandem Bikes The Race is back ! For the kickoff of The Amazing Race Season 38, Brice is switching things up on the Pitstop. While Brooke is living her best life in Europe, our good friend Sasha Joseph (@funsize_04) steps in to break down all the twists and turns of Episode 1. From icy strikes on the rink, cheese wheels in Edam, to flower power in the greenhouse, Brice and Sasha are just vibin' as they unpack the premiere. We're talking Express Pass drama, Hazard struggles, and first impressions of this Big Brother–meets–Race cast. You already know the vibes are high and the energy is flowing—don't miss it! You can also watch along on Brice Izyah's YouTube channel to watch us break it all down https://youtube.com/channel/UCFlglGPPamVHaNAb0tL_s7g Previously on the Purple Pants Podcast Feed:Purple Pants Podcast Archives LISTEN: Subscribe to the Purple Pants podcast feed WATCH: Watch and subscribe to the podcast on YouTubeSUPPORT: Become a RHAP Patron for bonus content, access to Facebook and Discord groups plus more great perks! Learn more about your ad choices. Visit megaphone.fm/adchoices
© 2020-2025 Ivy Podcast Discovery LLC
